Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Sanofi India Ltd (SANOFI)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500674 NSE: SANOFI Pharmaceuticals & Drugs | Small Cap | Sanofi India Share Price
₹3,060.45 4.35 (0.14%)
As on 23-Sep'26 11:43
Sanofi India Ltd (SANOFI)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500674 NSE: SANOFI Pharmaceuticals & Drugs | Small Cap | Sanofi India Share Price
₹3,060.45 4.35 (0.14%)
As on 23-Sep'26 11:43
Key Metrics
Valuation Multiples
Market Cap
₹7,038 Cr.
Current Price
₹3,060.5
52-Week Low / High
₹3,053 / 5,048
TTM EPS
₹179.5
TTM Sales
₹2,013 Cr.
Book Value per Share
-
P/E Ratio
17.03
Lower than its 5-year historical median
Industry PE
54.8
Price to Book (P/B)
0.00
Lower than its 5-year historical median
Price to Sales (P/S)
3.50
Lower than its 5-year historical median
EV/EBITDA
13.29
Lower than its 5-year historical median
Dividend Yield
3.82%
Profitability Efficiency
Return on Equity (ROE)
36.10%
Outperforms industry median
Return on Capital Employed (ROCE)
46.16%
Outperforms industry median
Return on Assets (ROA)
6.69%
Operating Profit Margin
24.4%
Net Profit Margin
15.58%
Gross Profit Margin
24.5%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
-8.73%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
0.66%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
-13.96%
Asset Quality
Promoter Holding
60.40%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹768 Cr.
Equity
₹23 Cr.
Face Value
₹10
All Time Low / High
₹235.05 / 10526.05
Check Before You Invest
Quality
Somewhat GoodValuation
FairCheck Valuation charts
Price Trend
Weak
Is Sanofi India Ltd a good quality company?
Sanofi India Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Sanofi India Ltd performance compare with that of its Peers?
Revenue growth of Sanofi India Ltd vs industry peers?
Sanofi India Ltd revenue CAGR is 45.27%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Sanofi India Ltd?
Promoters hold 60.40% of the Sanofi India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Sanofi India Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -3.3% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sanofi India Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 27.5% | 26.4% | 28.8% | 25.8% | 29.8% | 58% | 49.5% | 46.3% | 46.2% | 55.5% | - |
| Value Creation Index ⓘ | 1.0 | 1.0 | 1.1 | 0.9 | 1.2 | 3.3 | 2.7 | 2.4 | 2.4 | 3.1 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 2,367 | 2,464 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 1,996 | 2,013 | 1,837 | 1,805 |
| Sales YoY Gr. | - | 4.1% | 12.5% | 10.8% | -5.5% | 1.9% | -6.3% | -27.9% | 0.9% | -8.7% | - |
| Adj EPS ⓘ | 131.3 | 139.9 | 163.5 | 197.9 | 220.9 | 259.2 | 229.4 | 153.1 | 146.9 | 149.6 | 140.6 |
| YoY Gr. | - | 6.6% | 16.8% | 21.1% | 11.6% | 17.4% | -11.5% | -33.3% | -4.1% | 1.9% | - |
| BVPS (₹) ⓘ | 810.7 | 869.9 | 950.2 | 1,043.5 | 897.8 | 941.5 | 527.7 | 411.8 | 344 | 294.5 | 358.7 |
| Adj Net Profit ⓘ | 302 | 322 | 377 | 456 | 509 | 597 | 528 | 352 | 338 | 344 | 324 |
| Cash Flow from Ops. ⓘ | 322 | 435 | 374 | 412 | 611 | 559 | 399 | 231 | 462 | 438 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -2.8% | -8.7% | -12.8% | -8.7% | ||||
| Adj EPS ⓘ | 1.5% | -7.5% | -13.3% | 1.9% | ||||
| BVPSⓘ | -10.6% | -20% | -17.7% | -14.4% | ||||
| Share Price | -3.3% | -17.9% | -24.5% | -38.9% | ||||
Key Financial Parameters ⓘ
| Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 17.2 | 16.5 | 17.7 | 19.6 | 22.3 | 27.5 | 30.2 | 30.8 | 36.1 | 42.8 | 43.1 |
| Op. Profit Mgn % ⓘ | 22.6 | 21.9 | 22.6 | 21.7 | 24.7 | 25.8 | 25.4 | 24.5 | 24.4 | 26.7 | 26.7 |
| Net Profit Mgn % ⓘ | 12.8 | 13.1 | 13.6 | 14.9 | 17.5 | 20.2 | 19.1 | 17.7 | 16.8 | 18.8 | 17.9 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 156 | 287 | 379 | 386 | 419 | 436 | 446 | 656 | 661 | 692 | 93 |
| Cash Conv. Cycle ⓘ | 50 | 31 | 20 | 18 | 13 | 2 | -3 | 48 | 32 | 9 | 37 |
Valuation of Sanofi India - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Dec'03 | Dec'04 | Dec'23 | Dec'24 |
|---|---|---|---|---|
| Sales | 657 | 743 | 1,996 | 2,013 |
| Operating Expenses ⓘ + | 503 | 511 | 1,509 | 1,523 |
| Operating Profit ⓘ | 154 | 231 | 487 | 490 |
| Operating Profit Margin (%) | 23.4% | 31.1% | 24.4% | 24.4% |
| Other Income ⓘ + | 14 | 20 | 62 | 17 |
| Interest ⓘ | 0 | 0 | 2 | 2 |
| Depreciation ⓘ | 19 | 19 | 37 | 37 |
| Profit Before Tax ⓘ | 156 | 239 | 529 | 431 |
| Tax ⓘ | 51 | 83 | 164 | 118 |
| Profit After Tax | 105 | 156 | 365 | 314 |
| PAT Margin (%) | 15.9% | 21.0% | 18.3% | 15.6% |
| Adjusted EPS (₹) | 45.4 | 67.7 | 262.1 | 179.7 |
| Dividend Payout Ratio (%) | 35.20% | 23.60% | 63.70% | 65.10% |
| PARTICULARS | Dec'03 | Dec'04 | Dec'23 | Dec'24 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 346 | 454 | 947 | 791 | |||||||
| Debt + | 16 | 20 | 0 | 0 | |||||||
| Minority Interest | 0 | 0 | 0 | 0 | |||||||
| Trade Payables | 41 | 40 | 292 | 406 | |||||||
| Others Liabilities ⓘ | 93 | 91 | 3,465 | 3,482 | |||||||
| Total Liabilities ⓘ | 496 | 606 | 4,703 | 4,679 | |||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 165 | 167 | 315 | 313 | |||||||
| CWIP ⓘ | 14 | 3 | 16 | 18 | |||||||
| Investments ⓘ | 0 | 0 | 0 | 0 | |||||||
| Inventories | 95 | 111 | 664 | 500 | |||||||
| Trade Receivables | 47 | 93 | 132 | 230 | |||||||
| Cash Equivalents | 135 | 180 | 407 | 295 | |||||||
| Others Assets ⓘ | 39 | 51 | 3,170 | 3,324 | |||||||
| Total Assets ⓘ | 496 | 606 | 4,703 | 4,679 | |||||||
| PARTICULARS | Dec'03 | Dec'04 | Dec'23 | Dec'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 82 | 85 | 230 | 462 |
| Cash Flow From Investing Activity ⓘ + | -22 | 2 | 38 | -19 |
| Cash Flow From Financing Activity ⓘ + | -45 | -42 | -878 | -392 |
| Net Cash Flow ⓘ | 15 | 45 | -610 | 50 |
| PARTICULARS | Dec'03 | Dec'04 | Dec'23 | Dec'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 31.91 | 40.83 | 52.72 | 36.1 | ||||||
| ROCE (%) | 45.43 | 59.81 | 72.06 | 46.16 | ||||||
| Asset Turnover Ratio | 1.43 | 1.45 | 0.78 | 0.44 | ||||||
| PAT to CFO Conversion(x) | 0.78 | 0.54 | 0.63 | 1.47 | ||||||
| Working Capital Days | ||||||||||
| Receivable Days | 24 | 32 | 19.80 | 32 | ||||||
| Inventory Days | 48.90 | 47.20 | 68.20 | 102.90 | ||||||
| Payable Days | 48.20 | 47 | 63.50 | 130 | ||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Sanofi India Ltd FAQs
The current trading price of Sanofi India on 23-Sep-2026 11:43 is ₹3,060.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Sanofi India stood at ₹7,038.4 Cr
The latest P/E ratio of Sanofi India as of 22-Sep-2026 is 21.74.
The latest P/B ratio of Sanofi India as of 22-Sep-2026 is 8.52.
The 52-week high of Sanofi India is ₹5,047.9 and the 52-week low is ₹3,052.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sanofi India is ₹1,805 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanofi India Ltd is a average quality company.
The key valuation ratios of Sanofi India Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sanofi India Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Sanofi India Ltd
Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.
Business area of the company
The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
Products
Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).
Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)
Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)
Milestones
- 2013: Sanofi India launches Combiflam Plus.
- 2013: Sanofi ties up with IDF, PHFI to fight against diabetes among children in India.
- 2013: Sanofi India inks pact with Suzlon Energy for renewable energy.
- 2014: Sanofi India - Diabetic Teen from Pune achieves unique feat.
- 2014: Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
- 2015: Sanofi delivers 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur to support the immunization of children from five pediatric diseases.
- 2016: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research.
- 2018: Sanofi receives positive CHMP opinion for dengue vaccine.
- 2018: Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure.
- 2019: Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
- 2020: Sanofi Completes Acquisition of Synthorx, Inc.
- 2020: Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
- 2020: Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas.
You have 45 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
